Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council
US And EU Defend Current Innovation Model
Executive Summary
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
You may also be interested in...
WTO Price Transparency Talks Face Resistance From Developed Countries
Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.